Gabriele Multhoff, PhD
Gabriele Multhoff is Professor of Experimental Radiation Oncology and Radiobiology in the Department of Radiation Oncology at the Technische Universität München (TUM) and Head of the Radiation Immuno-Oncology Research Group at the TranslaTUM – Central Institute for Translational Cancer Research at TUM, Munich, Germany. Gabriele Multhoff is also Founder, former CEO and current CSO of Multimmune GmbH, Munich, Germany, a private clinical-stage biopharmaceutical company. In 2002 she became a Professor of Experimental Hematology at the University Hospital Regensburg. For more than 15 years, Gabriele Multhoff has focused on the development of innovative NK cell-based immunotherapies, therapeutic antibodies and targeting nanoparticles based on selective expression of heat shock proteins. At the TU München, Gabriele Multhoff initiated a proof-of-concept phase II clinical trial to evaluate an NK cell mediated immunotherapeutic approach based on heat shock proteins (HSP) to improve the clinical outcome of NSCLC patients following radio(chemo)therapy. Gabriele Multhoff’s research group is also identifying tumor-specific biomarkers for multimodal tumor imaging and theranostic purposes. Gabriele Multhoff has over 200 papers in peer-reviewed journals and is a named inventor on over 10 filed patents.
A. Graham Pockley, PhD
Graham Pockley is Professor of Immunobiology and former Director of the John van Geest Cancer Research Centre at Nottingham Trent University, UK; Founder and CEO of Chromocyte Limited, Sheffield, UK and CEO of Multimmune GmbH, Munich, Germany, a private clinical-stage biopharmaceutical company. Previously he directed the experimental transplantation programme in the Professorial Surgical Unit at the Medical College of St. Bartholomew´s Hospital, London and later was appointed Professor of Immunobiology at the University of Sheffield in the UK where he retains an Honorary Professorship in the Department of Oncology and Metabolism. His research focus for the last 20 years has been on the development of innovative therapeutics and diagnostics in immuno-oncology. He is an inventor on a granted patent (PAP-based vaccine for prostate cancer) and on a submitted patent relating to the diagnosing and staging of prostate cancer using peripheral blood phenotypic profiling and machine learning. He has accumulated a portfolio of over 200 peer-reviewed publications.
Rudolf M. Huber, MD
Rudolf Huber is Professor of Medicine at Ludwig-Maximilians-University Munich, is past head of the Department of Respiratory Medicine and Thoracic Oncology at the University hospitals – campus Innenstadt. He chaired the Thoracic Oncology Centre Munich and is cofounder and member of the comprehensive Pneumology Centre of Munich (CPC-M) and the German Centre for Lung Research (DZL). His work is focused on Thoracic Oncology. He is an active member/initiator of international task forces and (past) board member of the German Respiratory Society, European Respiratory Society, AIO of the German Cancer Society, Regent of IASLC for Europe and Governor for Germany of ACCP. He is actively involved in patient care and was long-term responsible for teaching in Respiratory Medicine and Thoracic Oncology at the University of Munich. He has more than 400 publications in peer-reviewed journals.